-
Mashup Score: 0Pembrolizumab/Chemotherapy for Advanced Biliary Tract Cancer - 4 hour(s) ago
On October 31, 2023, pembrolizumab (Keytruda) was approved for use with gemcitabine/cisplatin in first-line treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. 1 Approval was based on the double-blind KEYNOTE-966 trial (ClinicalTrials.gov identifier NCT04003636). In this study, patients were randomly assigned to receive pembrolizumab at 200 mg (n = 533) or placebo (n = 539) on day 1 with gemcitabine at 1,000 mg/m 2 and cisplatin at 25 mg/m 2 on days 1 and 8
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 11Survey Finds Majority of Patients With Cancer and Survivors Have or Expect to Incur Medical Debt—Even Those With Insurance - 14 hour(s) ago
Nearly half of patients with cancer and cancer survivors report being burdened by medical debt, alongside some who report expecting to incur medical debt as part of their treatment plan, according to …
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Pembrolizumab/Chemotherapy for Advanced Biliary Tract Cancer - 16 hour(s) ago
On October 31, 2023, pembrolizumab (Keytruda) was approved for use with gemcitabine/cisplatin in first-line treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. 1 Approval was based on the double-blind KEYNOTE-966 trial (ClinicalTrials.gov identifier NCT04003636). In this study, patients were randomly assigned to receive pembrolizumab at 200 mg (n = 533) or placebo (n = 539) on day 1 with gemcitabine at 1,000 mg/m 2 and cisplatin at 25 mg/m 2 on days 1 and 8
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Belzutifan in Previously Treated Advanced Renal Cell Carcinoma - 18 hour(s) ago
On December 14, 2023, the hypoxia-inducible factor inhibitor belzutifan (Welireg) was approved for patients with unresectable locally advanced or metastatic clear cell renal cell carcinoma with disease progression on previous treatment with a PD-1 or PD-L1 inhibitor and a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor. 1 Belzutifan has a boxed warning for embryofetal toxicity. It also has warnings/precautions for anemia and hypoxia. Approval was based on the open-label LITESPARK-005
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Enfortumab Vedotin-ejfv Plus Pembrolizumab Improves Survival vs Platinum-Based Chemotherapy in Advanced Urothelial Cancer - 19 hour(s) ago
The phase III EV-302 trial has shown that the combination of the antibody–drug conjugate enfortumab vedotin-ejfv, which is directed against nectin-4, and the PD-1 inhibitor pembrolizumab improved prog…
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Cell-Free DNA Blood-Based Test and Next-Generation Multitarget Stool DNA Test in Colorectal Cancer Screening - 20 hour(s) ago
In two studies reported in The New England Journal of Medicine, investigators found that a cell-free DNA blood-based test (ECLIPSE study) and a next-generation multitarget stool DNA test (BLUE-C study…
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 143Bishoy Faltas, MD, Named Chief Research Officer of the Englander Institute for Precision Medicine at Weill Cornell Medicine - 21 hour(s) ago
Olivier Elemento, PhD, Director of the Englander Institute for Precision Medicine (EIPM) at Weill Cornell Medicine, New York, recently announced that Bishoy M. Faltas, MD, has been named Chief Researc…
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10KEYNOTE-756 Additional Findings: Pembrolizumab Shown to Be Beneficial Regardless of Age, Menopausal Status - 22 hour(s) ago
In updated findings from the phase III KEYNOTE-756 trial, the addition of pembrolizumab to chemotherapy in the neoadjuvant setting improved the rates of pathologic complete response for patients with…
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 21
Analysis of long-term findings from the phase III Dana-Farber Cancer Institute Trial 05-043 showed that whole-pelvic radiation therapy was associated with favorable survival outcomes vs prostate-only …
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 19AI in Cancer Care: Embrace the Change - 3 day(s) ago
According to Google Chief Executive Officer Sunder Pichai, artificial intelligence (AI) is “the most profound technology humanity is working on—more profound than fire or electricity or anything that …
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet
In the Clinic: Pembrolizumab/Chemotherapy for Advanced Biliary Tract Cancer https://t.co/fXnUXdjGGq #hpbcsm #biliarytractcancer #oncology #immunotherapy